We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Institute for Clinical and Economic Review (ICER) issued its final word on Biogen’s newly approved and very controversial $56,000-a-year Alzheimer’s drug Aduhelm (aducanumab) Thursday, and that word is “no.” Read More
In a late-stage trial, the vaccine proved to be 100 percent effective in preventing moderate and severe disease, and more than 90 percent effective at preventing symptomatic infections. Read More
Sanofi plans to spend $3.2 billion to buy clinical-stage messenger-RNA (mRNA) therapeutics company Translate Bio, deepening its holdings in the mRNA space to develop new therapeutics and vaccines. Read More
The U.S. District Court for the Eastern District of Pennsylvania dismissed the case “with prejudice,” meaning that the court intends for the dismissal to be final in all courts. Read More